Basic Information
| LncRNA/CircRNA Name | HOXA-AS2 |
| Synonyms | HOXA-AS2, HOXA3as |
| Region | GRCh38_7:27107777-27134302 |
| Ensemble | ENSG00000253552 |
| Refseq | NR_122069 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Adriamycin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qPCR assays, Luciferase reporter assay, other |
| Sample | AML cell lines, U937 and THP-1 |
| Expression Pattern | up-regulated |
| Function Description | HOXA-AS2 is significantly upregulated in BM samples from AML patients after treatment with adriamycin-based chemotherapy and in U/A and T/A cells. Knockdown of HOXA-AS2 inhibited ADR cell proliferation in vitro and in vivo and promoted apoptosis. Bioinformatics online programs predicted that HOXA-AS2 sponge miR-520c-3p at 3'-UTR with complementary binding sites, which was validated using luciferase reporter assay and anti-Ago2 RIP assay. HOXA-AS2 could negatively regulate the expression of miR-520c-3p in ADR cells. S100A4 was predicted as a downstream target of miR-520c-3p, which was confirmed by luciferase reporter assay. |
| Pubmed ID | 30466095 |
| Year | 2018 |
| Title | Knockdown of Long Noncoding RNA HOXA-AS2 Suppresses Chemoresistance of Acute Myeloid Leukemia via the miR-520c-3p/S100A4 Axis. |
External Links
| Links for HOXA-AS2 | GenBank HGNC NONCODE |
| Links for acute myeloid leukemia | OMIM COSMIC |